dailynewsnblog
The webinar will examine how manufacturers can evaluate the Dominican Republic within a more resilient and collaborative U.S. MedTech supply chain. Schad’s analysis moves beyond factory price to consider the U.S. Trade Representative’s July 2026 action under Section 301, which imposed an additional 12.5% tariff on Dominican Republic-origin products subject to specified exemptions, alongside logistics, transit time, inventory, working capital, quality coordination and disruption risk. Even after that tariff increase, Schad’s updated findings indicate that the Dominican Republic’s total cost of manufacturing for U.S.-bound medical devices remains more competitive than China’s, as shorter lead times, lower inventory and logistics costs, and reduced supply-chain risk continue to offset the tariff differential. The updated presentation will reflect the latest U.S. trade-policy environment and its implications for nearshoring decisions.
